ZLAB
Zai Lab Limited17.00
-0.34-1.96%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Zoci details sharpen; no '26 guidance
Q&A drilled into zoci's brain met advantages—rapid responses avoiding local therapy delays, preventing relapses—with RANO data due H1 and NEC readout from 60 second-line patients, eyeing single-arm approval while planning first-line chemo-sparing Ph3 by year-end. No full 2026 guidance emerged amid VYVGART pricing/rebate flux and hospital patterns, though top-line growth is expected from XACDURO, KarXT Q2 launch at 800 sites, and TIVDAK. VYVGART cycles rose over 50% YoY toward guideline minimum of three via affordability aids. China fills 30% of zoci Ph3 slots, accelerating timelines. Breakeven stays a goal sans timing. Execution tone firm; watch H1 catalysts.
Key Stats
Market Cap
1.88BP/E (TTM)
-Basic EPS (TTM)
-1.90Dividend Yield
0%Recent Filings
8-K
Revenues up 17% y-o-y
Zai Lab reported Q4 2025 revenues of $127.6 million, up 17% y-o-y, and full-year $460.2 million, up 15%, driven by XACDURO and NUZYRA growth despite VYVGART rebates. Net loss narrowed to $50.4 million from $81.7 million. Pipeline advances rapidly; zoci nears three registration studies by 2026 end. Cash stands at $789.6 million.
10-K
FY2025 results
Zai Lab posted FY2025 net loss of $175.5M, improved 32% y/y amid 15% revenue growth to $460.2M driven by XACDURO's 593% surge from hospital adoption despite supply constraints and NUZYRA's 41% gain on market penetration; ZEJULA held as top PARP inhibitor while VYVGART/VYVGART Hytrulo absorbed NRDL rebates. Q4 momentum built with AUGTYRO NTRK+ approval and KarXT schizophrenia nod, plus pipeline wins like zoci Phase 1 data. Cash at $789.6M funds operations; $204.5M short-term debt supports working capital. Chinese government intervention risks quarterly momentum.
8-K
Q3 revenues up 14%
Zai Lab reported Q3 2025 revenues of $116.1 million, up 14% year-over-year, while operating loss narrowed 28% to $48.8 million ($28.0 million adjusted). Product sales hit $115.4 million, led by VYVGART at $27.7 million despite a price adjustment, yet ZEJULA dipped to $42.4 million amid competition. Pipeline advances rapidly: zoci registrational study launched in 2L+ ES-SCLC. Full-year revenue guidance raised to at least $460 million.
10-Q
Q3 FY2025 results
Zai Lab posted Q3 revenue of $116.1M, up 14% y/y from $102.3M, driven by 54% y/y growth in NUZYRA to $15.4M and XACDURO's $6.4M launch, though ZEJULA dipped 12% y/y to $42.4M amid PARPi competition. Operating loss narrowed to $48.8M from $67.9M y/y as R&D fell 27% on lower licensing fees, while gross margin on products held steady. Diluted EPS improved to -$0.03 from -$0.04, confirmed against 1.10B weighted shares. Cash swelled to $717.2M with $203.0M short-term debt at 2.63% (working capital loans). Operating cash burn eased to $124.8M YTD. New pipeline advances continue. China forex controls crimp dividend flows.
8-K
RMB300M credit facility signed
Zai Lab secured a RMB300 million (~$42.1M) revolving credit facility from Industrial Bank Shanghai Gubei Branch for its Shanghai subsidiary's working capital, guaranteed by the parent, effective October 13, 2025 to May 5, 2026. No draws yet. Facility imposes covenants restricting mergers, equity transfers, and debt hikes without consent.
IPO
Employees
Sector
Industry
INVA
Innoviva, Inc.
19.92-0.22
JAZZ
Jazz Pharmaceuticals plc
169.73+0.20
KAPA
Kairos Pharma, Ltd.
0.74+0.00
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
LIANY
LianBio
0.09+0.00
MRVI
Maravai LifeSciences Holdings,
3.59-0.08
PBYI
Puma Biotechnology Inc
5.67-0.15
XNCR
Xencor, Inc.
16.55-0.24
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02
ZURA
Zura Bio Limited
4.12+0.05